Berlin, Germany-based caprotec bioanalytics focuses on the commercialisation of its proprietary Capture Compound Mass Spectrometry (CCMS) technology.
Prior to joining caprotec, Metternich was the vice president and head of Basic Research Site at Merck & Co in West Point, PA.
Before joining Meck, Metternich was the executive vice president and member of the executive committee at Schering AG in Berlin.
caprotec founder and CEO Hubert Koster said that they are delighted to have him join caprotec’s management team. His leadership experience, comprehensive knowledge of the drug discovery and development process, and international research network are exactly what we need for the future growth of our company.”